Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 17
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Cofactors facilitate bona fide prion misfolding in vitro but are not necessary for the infectivity of recombinant murine prions

  • Pérez-Castro, Miguel Ángel
  • Eraña, Hasier|||0000-0001-8776-4211
  • Vidal Barba, Enric|||0000-0002-4965-3286
  • Charco, Jorge M.|||0000-0003-3476-1855
  • Lorenzo, Nuria L.
  • Gonçalves-Anjo, Nuno|||0000-0003-0586-2550
  • Galarza-Ahumada, Josu|||0000-0003-0275-559X
  • Díaz-Domínguez, Carlos M.|||0000-0002-0410-1963
  • Piñeiro, Patricia|||0000-0002-0062-2542
  • González-Miranda, Ezequiel
  • Giler, Samanta
  • Telling, Glenn
  • Sánchez-Martín, Manuel A.|||0000-0001-8370-1336
  • Garrido, Joseba M.
  • Geijo, Maria V.|||0000-0002-3120-1038
  • Requena, Jesús R.
  • Castilla, Joaquín|||0000-0002-2216-1361
Prion diseases, particularly sporadic cases, pose a challenge due to their complex nature and heterogeneity. The underlying mechanism of the spontaneous conversion from PrP C to PrP Sc, the hallmark of prion diseases, remains elusive. To shed light on this process and the involvement of cofactors, we have developed an in vitro system that faithfully mimics spontaneous prion misfolding using minimal components. By employing this PMSA methodology and introducing an isoleucine residue at position 108 in mouse PrP, we successfully generated recombinant murine prion strains with distinct biochemical and biological properties. Our study aimed to explore the influence of a polyanionic cofactor in modulating strain selection and infectivity in de novo -generated synthetic prions. These results not only validate PMSA as a robust method for generating diverse bona fide recombinant prions but also emphasize the significance of cofactors in shaping specific prion conformers capable of crossing species barriers. Interestingly, once these conformers are established, our findings suggest that cofactors are not necessary for their infectivity. This research provides valuable insights into the propagation and maintenance of the pathobiological features of cross-species transmissible recombinant murine prion and highlights the intricate interplay between cofactors and prion strain characteristics. Prion diseases are rare and complex neurodegenerative disorders that can occur spontaneously, through a poorly understood conformational or structural change of normal, physiological prion protein. This abnormally structured form, known as prion, acquires the capacity to induce the same transformation to surrounding prion proteins, leading to disease. In our study, we take advantage of a recently developed methodology that closely mimics this process in a test tube using extremely simple components. Applying this system and modifying a specific part of the mouse prion protein, we were able to generate different prion strains with unique characteristics spontaneously. This process is greatly enhanced using an additional molecule called cofactor, that has been proposed to affect the variability and infectivity (capacity to cause disease in an animal model) of these prions. Our findings show that while cofactors facilitate the spontaneous formation of prions and may influence their final characteristics, they are not necessary for their infectivity nor for their spontaneous formation. This research gives new insights into the role cofactors play in the spontaneous generation of prions and their behavior in animal models.
RIUMA. Repositorio Institucional de la Universidad de Málaga
Publicación Artículo científico (JournalArticle)

Systematic review on genetic polymorphisms associated with idiosyncratic drug-induced liver injury (iDILI): iDILInet as an interactive visualization tool

  • Matilla-Cabello, Gonzalo
  • Remesal-Doblado, Ángela
  • Celebi-Cinar, Muzzez
  • Bodoque-García, Ana
  • Betul Metin, Fatma
  • Rezaei, Aida
  • Aftab, Moiz
  • De los Santos-Fernández, Romina
  • Segovia-Zafra, Antonio
  • Álvarez-Álvarez, Ismael
  • Andrade-Bellido, Raúl Jesús
  • Cakan-Akdogan, Gulcin
  • Lucena-González, María Isabel
  • Konu, Ozlen
  • Villanueva-Paz, Marina
Idiosyncratic drug-induced liver injury (iDILI) is a rare, dose-independent and unpredictable adverse reaction occurring at therapeutic drug exposure, and it presents a significant challenge for drug development and patient safety. Despite extensive research, genetic susceptibility to iDILI remains poorly understood. We conducted a comprehensive systematic study of 139 human genetic studies to identify and characterize genetic polymorphisms associated with increased risk or protection against iDILI. Our study included candidate gene studies and genome-wide association studies (GWAS), encompassing 83 risk and 25 protective genes, with NAT2, HLA-B, and SLCO1B1 among the most frequently reported. We performed functional enrichment analyses using KEGG and Gene Ontology, revealing key biological pathways related to immune response, xenobiotic metabolism, and bile secretion. To enhance data accessibility and interpretation, we developed iDILInet, a publicly available web application that enables interactive exploration and network-based visualization of iDILI-associated gene-variant-drug relationships, enriched with liver-specific expression data from the Human Protein Atlas (HPA). Our work provides a novel integrative resource that supports ongoing efforts in precision medicine and pharmacogenomics and represents a significant advancement in implementing living systematic reviews in toxicogenomics., Consejería de Salud de Andalucía, Instituto de Salud Carlos III, Fondo Europeo de Desarrollo Regional, Agencia Española del Medicamento y Productos Sanitarios, Ministerio de Ciencia, Innovación y Universidades, Agencia Estatal de Investigación, Universidad de Málaga
RIUMA. Repositorio Institucional de la Universidad de Málaga
Publicación Artículo científico (JournalArticle)

Epigenetic modifications in drug-induced liver injury: A systematic review

  • de los Santos-Fernández, Romina Lorena
  • Segovia-Zafra, Antonio
  • Paz-López, Guillermo
  • Matilla-Cabello, Gonzalo
  • Niu, Hao
  • Álvarez-Álvarez, Ismael
  • Stephens, Camilla
  • Lucena-González, María Isabel
  • Andrade-Bellido, Raúl Jesús
  • Medina-Cáliz, Inmaculada
Genetic susceptibility has been identified in idiosyncratic drug-induced liver injury, a potentially severe adverse reaction towards drugs, herbal products and dietary supplements. However, its occurrence cannot be fully explained by the presence of genetic variants in specific genes, suggesting that other factors are involved. Druginduced liver injury epigenetic signatures could help explain genetic regulatory mechanisms behind this disease and might provide disease biomarkers. This systematic review aims to analyse all available information on epigenetic risk association studies in drug-induced liver injury. The main inclusion criterion was population studies on idiosyncratic drug-induced liver injury with significant risk association analysis between drug-induced liver injury and an epigenetic regulation mechanism. Out of the 7 included articles, 6 focused on DNA methylation and 1 on long noncoding RNA. All of the studies were on antituberculosis drug-induced liver injury and came from Asia. CpG site methylation in the CYP2D6 (odds ratio: 9.19, 95% confidence interval: 3.26–25.89, P < .001) and NAT2 (odds ratio: 8.37, 95% confidence interval: 2.39–29.32, P = .001) promoters conferred the highest risk. Hypomethylation of LINE-1 and Alu transposable elements has potential as antituberculosis drug-induced liver injury biomarkers, showing an area under the curve value of 0.94. To conclude, the studies mainly focused on DNA methylation modifications associated with antituberculosis drug-induced liver injury, with all of them coming from Asia, where tuberculosis is a public health burden. Despite the lack of knowledge in this area, the evidence has shown that DNA methylation alterations in antituberculosis drug-induced liver injury could have potential as a new diagnostic and therapeutic target., Instituto de Salud Carlos III, Agencia Estatal de Investigación, CIBER, European Comission
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Disruption of MCL1/BOK transmembrane interaction as a novel strategy to induce cell death in tumours

  • Buffa, M.
  • Leiva, D.
  • García-Jareño, A.
  • Garcés-Flores, M.
  • Díaz, E.
  • Lucantoni, F.
  • Telechea, M.
  • Chen, L.
  • Lucendo, E.
  • Shalaby, R.
  • Lolicato, F.
  • Kulig, W.
  • García-Sáez, A.J.
  • Moreno-Bueno, G.
  • Sancho, M.
  • Orzáez-Calatayud, Mar
[EN] MCL1, an anti-apoptotic BCL-2 family member, is frequently overexpressed in multiple tumour types and correlates with poor prognosis; however, targeting its cytosolic domain to release pro-apoptotic effectors has been limited by cardiotoxicity in clinical trials. In this study, we describe a chemically mediated disruption of the MCL1/BOK transmembrane interaction that induces tumour cell death without affecting viability in 3D cardiomyocyte cultures. Molecular dynamics simulations and LUV-based assays converged to show that the MBoIN179 disrupts transmembrane dimerization, thereby restoring BOK pore formation inhibited by MCL1. In cells, interference with the MCL1/BOK transmembrane interaction promoted relocalization of BOK from the endoplasmic reticulum to mitochondria, where it engaged a BOK-dependent cell death program in both 2D and 3D breast cancer models, leading to reduced tumour growth and metastasis in vivo. Analysis of patient tumour microarrays further showed that BOK is overexpressed in aggressive breast cancer subtypes and correlates with poor prognosis. Together, these findings identify the MCL1/BOK transmembrane interaction as a tumour-selective vulnerability that can be engaged to promote antitumour responses with cardiac safety, highlighting transmembrane interactions as viable molecular targets., These results are part of the project PID2023-148234NB-I00, funded by MCIU/AEI/ 10.13039/501100011033 and ERDF/EU, project PT23/00177, funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union, and the project CIPROM/2022/62, funded by the Department of Education, Culture, Universities and Employment of the Generalitat Valenciana (PROMETEO). A part of the work was also supported by grants from the Spanish Ministry of Economy and Innovation (PID2019- 104644RB-I00 -GMB-) and the Instituto de Salud Carlos III (CIBERONC, CB16/12/00295 -GMB). MB is funded by a predoctoral fellowship (GRISOLIAP/2021/132) from Generalitat Valenciana and by an EMBO Scientific Exchange Grant (11082) for a research stay in the laboratory of Ana García-Sáez. DL is funded by a predoctoral fellowship (PRDVA21475LEIV) from the Spanish Cancer Association (AECC). RS and AGS are partially funded by the Deutsche Forschungsgemeinschaft (CRC1403, project 414786233; TRR353, project 471011418). This work is also supported by grants of the Deutsche Forschungsgemeinschaft (DFG) to FL (SFB-1638/1 511488495 - Z01).
Minerva. Repositorio Institucional de la Universidad de Santiago de Compostela
Publicación Artículo científico (JournalArticle)

Variables associated with endogenous hyperinsulinism in hypoglycemia diagnosis. Could the 72-hour fasting test be shortened in low-risk patients?

  • González Vidal, Tomás
  • Gude Sampedro, Francisco
  • Menéndez-Torre, Edelmiro
Background: The 72-hour fasting test remains the standard for the diagnosis of endogenous hyperinsulinism. We investigated which variables could identify patients at low risk for endogenous hyperinsulinism, in whom a shortening of the 72-hour fasting test could be considered. Methods: This multicenter, retrospective study included 64 individuals (46 women, median age 45 years) without diabetes who underwent 72-hour fasting tests for the etiologic diagnosis of hypoglycemia. Pre- and intra-test variables were collected, including point-of-care glucose trajectories during the test. Testing was stopped before 72 h if symptomatic serum glucose <55 mg/dL or asymptomatic serum glucose ≤45 mg/dL occurred. Endogenous hyperinsulinism was diagnosed in individuals who had serum glucose <55 mg/dL, serum insulin ≥3.0 μU/mL, and serum C-peptide ≥0.6 ng/mL. Results: Patients with endogenous hyperinsulinism (n = 10) had steeper descending point-of-care glucose trajectories (p < 0.001) than those without it. Older age and lower minimum pre-test serum glucose concentrations were independently associated with endogenous hyperinsulinism. A calculator for probability prediction of endogenous hyperinsulinism was developed including these variables and sex (AUC = 0.94). Older age, female sex, lower body mass index, and lower minimum point-of-care glucose during the first 24 h of fasting were independently associated with serum glucose <55 mg/dL after the first 24 h of fasting. A calculator for predicting probability of serum glucose <55 mg/dL after the first 24 h of fasting was developed including these variables (AUC = 0.84). Conclusions: Pre- and intra-test variables can identify individuals at low risk for endogenous hyperinsulinism, in whom shortening the 72-hour fasting test could be considered.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

A Novel Multicompartment Barrier-Free Microfluidic Device Reveals the Impact of Extracellular Matrix Stiffening and Temozolomide on Immune-Tumor Interactions in Glioblastoma

  • Bayona, Clara
  • Olaizola-Rodrigo, Claudia
  • Sharko, Vira
  • Ashrafi, Mehran
  • Barrio, Jesús del
  • Doblaré, Manuel
  • Monge, Rosa
  • Ochoa, Ignacio
  • Oliván, Sara
The immune system plays a crucial role in shaping the glioblastoma tumor microenvironment, characterized by its complexity and dynamic interactions. Understanding the tumor-immune crosstalk is essential for advancing cancer research and therapeutic development. Here, a novel multicompartment, barrier-free microfluidic device is presented that overcomes the limitations of existing models by enabling direct tumor-immune interactions without physical barriers, preserving natural immune cell infiltration. This platform supports the independent and simultaneous culture of tumor and immune cells, replicating the healthy-tumoral stroma interface, and allows investigating the effect of matrix stiffness and chemotherapy on both populations. The findings reveal that increased collagen concentration promotes tumor invasiveness while impairing immune cell infiltration. Additionally, temozolomide treatment reduces immune cell motility but enhances anti-tumor immune responses. These insights highlight the critical roles of extracellular matrix mechanics and chemotherapy in tumor progression and immune modulation, establishing this device as a powerful tool for studying glioblastoma-immune dynamics and evaluating therapeutic strategies.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Optical fiber integration in PDMS devices for dynamic tissue deformation

  • Velarte, Antonio
  • Sannino, Andrea
  • Otin, Aranzazu
  • Santamaría, Beatriz
  • Artigas, José Ignacio
  • Pueyo, Esther
This study introduces an advanced optical fiber-based stretchable sensing platform designed for precise biomechanical characterization in tissue engineering applications, specifically tailored for cardiac tissue studies. The system is entirely fabricated from biocompatible polydimethylsiloxane (PDMS) material, and features a thin upper membrane and an internal cavity where controlled pneumatic deformation occurs. Deformation is quantified through changes in optical intensity measured through a strategically aligned optical fiber pair, as membrane stretching disrupts total internal reflection conditions. Finite element modeling using COMSOL is used to optimize device geometry and predict deformation, which is subsequently validated through experimental analyses. A custom-designed electronic system with capacity for real-time signal processing ensures stable and sensitive data acquisition. The experimental results show high levels of linearity and repeatability in a physiologically relevant stretch range, highlighting its potential for biomechanical research applications and dynamic tissue stimulation. Future improvements are directed toward extending the reliable deformation operating range through advances in the optical system.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Approaching gold‐standard sensitivity in a portable and versatile gold nanoprisms thermoplasmonic platform for lateral flow detection of biomolecules

  • Cuestas Ayllón, Carlos
  • Martín Barreiro, Alba
  • García Barrientos, África
  • Moros, María
  • Grazú Bonavía, Valeria
  • Martínez de la Fuente, Jesús
Plasmonic nanoparticles exhibit unique optical and thermal properties that make them ideal for next‐generation diagnostic technologies. Among them, gold nanoprisms (AuNPrs) are especially powerful due to their anisotropic geometry, tunable surface plasmon resonance in the near‐infrared (NIR) region, and high photothermal conversion efficiency. These features transform them from passive labels into active nanotransducers capable of amplifying diagnostic signals. Building on these advantages, we developed two AuNPr‐based sensing platforms: Thermo Lateral Flow Immunoassay (ThermoLFIA) and Thermo Oligonucleotide‐based Lateral Flow Assay (ThermoOLFA). By coupling AuNPrs with thermoresponsive substrates, both systems use localized heat generation to boost analytical sensitivity, enabling visual enhancement far beyond that of conventional gold spheres. ThermoLFIA demonstrated clinically relevant detection of gastrointestinal cancer biomarkers (CEA, CA19‐9, VEGF), outperforming standard ELISA tests. In parallel, functionalization of AuNPrs with DNA probes enabled ThermoOLFA to detect SARS‐CoV‐2 RNA with sensitivity comparable to RT‐qPCR, but without amplification steps and within 25 min. This proof‐of‐concept confirms that plasmonic nanoprisms can drive rapid, portable, and ultrasensitive diagnostics, opening a path toward point‐of‐care platforms with strong clinical and translational potential.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Antimicrobial therapy among hospitalized older adults with suspected infection and negative blood cultures

  • Pellejero-Sagastizabal, Galadriel
  • Morte-Romea, Elena
  • Girón Ortega, José Antonio
  • Paño-Pardo, José Ramón
  • Fernández Guerrero, Raquel
  • Guerrero, Francisca
  • Montes de Oca, Montserrat
  • Jiménez-Jorge, Silvia
  • Palacios-Baena, Zaira R.
  • Rodríguez-Baño, Jesús
  • Retamar-Gentil, Pilar
  • Montes de Oca Arjona, Montserrat
  • Galán Sánchez, Fátima
  • Rodríguez Mateos, María Eugenia
  • Girón-González, José Antonio
  • Martín Aspas, Andrés
  • Sánchez Tembleque, Claudio
  • Guerrero Sánchez, Francisca María
  • Morte-Romea, Elena
  • Pellejero-Sagastizabal, Galadriel
  • Luque Gómez, Pilar
  • Paño-Pardo, José Ramón
  • Sierra, José Luis
  • Letona Gimenez, Santiago
  • Palacián, Pilar
  • Rodriguez, Nora Mariela
  • Arenere Mendoza, Mercedes
  • Allende Bandrés, Maria Ángeles
  • Fresquet Molina, Raquel
  • Navarro Pardo, Irene
  • Girón Ortega, José Antonio
  • Fernández Guerero, Raquel
  • Retamar-Gentil, Pilar
  • Palacios-Baena, Zaira
  • de Cueto, Marina
  • Beltrán García, Margarita
  • Cantón Bulnes, María Luisa
  • Suarti, Lorenzo Roberto
  • Rodríguez-Baño, Jesús
Background Managing infections in older adults is challenging due to their unique characteristics, which often drives empirical antimicrobial use, increasing risks of adverse outcomes and antimicrobial resistance (AMR). Data on antimicrobial adequacy in older patients with suspected infection but negative blood cultures (BC) remain scarce, despite this being a common clinical scenario. Methods In this multicenter prospective cohort study (NO-BACT project) across three Spanish hospitals (2018–2019), we compared antimicrobial therapy adequacy between older adults (≥ 85 years) and younger patients with suspected infections and negative BC. Antimicrobial stewardship (AMS) experts evaluated treatment adequacy at days 2 and 5–7 using standardized guideline-based criteria. We assessed predictors of adequacy using logistic regression and examined clinical outcomes including 30-day mortality and length of hospital stay (LOS). Results Among 799 enrolled patients, 90 (11.3%) were older adults. While initial antimicrobial adequacy was comparable between groups at Day 2 (59.8% vs. 60.1%), older adults were significantly less likely to receive adequate treatment by Days 5–7 (adjusted OR 0.46, 95% CI 0.25–0.82, p = 0.009). The main drivers of inadequacy were excess antimicrobial spectrum (84.2%) and inappropriate route of administration (48.7%). Older adults demonstrated higher 30-day mortality (16.7% vs. 7.8%; p = 0.009) despite shorter LOS (8 vs. 10 days, p = 0.006), though treatment adequacy was not associated with mortality. Conclusions In older patients with negative BC, antimicrobial therapy shows high rates of inadequacy that worsen over time, primarily due to delayed de-escalation and prolonged intravenous therapy. These findings identify a clear target for AMS interventions focusing on timely treatment optimization.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Overexpression of bank vole PrP(I109) in mice induces a spontaneous atypical prion disease with sex-dependent onset, early NfL elevation, and universal prion strain permissiveness

  • Eraña, Hasier
  • Vidal, Enric
  • Fernández-Borges, Natalia
  • Charco, Jorge M.
  • Díaz‑Domínguez, Carlos M.
  • Sampedro-Torres-Quevedo, Cristina
  • San-Juan-Ansoleaga, Maitena
  • Fernández-Muñoz, Eva
  • Galarza-Ahumada, Josu
  • Pérez-Castro, Miguel Ángel
  • Gonçalves-Anjo, Nuno
  • Piñeiro, Patricia
  • Pirisinu, Laura
  • Di Bari, Michele Angelo
  • Giler, Samanta
  • Raimondi, Ilaria
  • Espinosa, Juan Carlos
  • Vanni, Ilaria
  • D’Agostino, Claudia
  • Rodríguez-Cuesta, Juan
  • Pasetto, Laura
  • Bonetto, Valentina
  • González-Martín, Nora
  • Teijeira, Susana
  • Zou, Wen-Quan
  • Geijo, Mariví
  • Torres, Juan María
  • Chiesa, Roberto
  • Sánchez‑Martín, Manuel A.
  • Nonno, Romolo
  • Requena, Jesús R.
  • Castilla, Joaquín
Transgenic mice overexpressing bank vole prion protein with the isoleucine 109 polymorphism, TgVole(I109)4x, develop spontaneous neurodegenerative disease with sex-dependent onset, averaging 170 days in females and 200 days in males at terminal stage. The clinical and pathological features closely resemble Gerstmann-Sträussler-Scheinker syndrome (GSS), with characteristic ataxia, dysmetria, kyphosis, and prominent PrP plaques. Biochemical analysis reveals an atypical prion protein banding pattern with a distinctive low molecular weight band (7–10 kDa) following proteinase K digestion, similar to other atypical prion diseases such as small ruminants atypical scrapie (AS). Importantly, these spontaneously generated prions are highly infectious when passaged to mice expressing the same I109 polymorphism as well as to wild bank voles carrying the I109 polymorphism, but not to models expressing the methionine variant at this position, demonstrating the critical role of this specific polymorphism in atypical prion propagation. Temporal analysis reveals that infectious prions emerge significantly (2–3 months) before clinical signs appear, offering important insights into the pre-clinical phase of prion diseases. Serum neurofilament light chain levels increase significantly at 80 days of age, approximately 100 days before clinical onset, providing a wide therapeutic window with a reliable biomarker. The TgVole(I109)4× model exhibits extraordinary versatility in propagating diverse prion strains, showing remarkable susceptibility to atypical prions (including GSS and AS) with exceptionally short incubation periods, while maintaining the ability to efficiently propagate classical and recombinant prion strains. We present here a thoroughly characterized transgenic mouse model that spontaneously develops an atypical, bona fide prion disease with sex-related differences in disease onset. This model offers valuable insights into spontaneous and atypical prionopathies while demonstrating exceptional versatility for studying diverse prion strains and potential utility for evaluating therapeutic interventions when used with appropriate study designs that account for individual variability., The present work was partially funded by five different grants awarded by “Agencia Estatal de Investigación, Ministerio de Ciencia e Innovación” (Spanish Government), grant numbers PID2024-160022OB-I00, PID2021-122201OB-C21 granted to J.C., PID2021-1222010B-C22 granted to E.V., and PID2023-146146NB-I00 to J.C.E. funded by MCIN/AEI/https://doi.org/10.13039/501100011033 and co-financed by the European Regional Development Fund (ERDF), UE and PID2020-117465GB-I00 granted to J.R.R., funded by MICIU/AEI/https://doi.org/10.13039/501100011033. EFA031/01 NEURO-COOP, which is co-funded at 65% by the European Union through Programa Interreg VI-A España-Francia-Andorra (POCTEFA 2021–2027) granted to J.C. and H.E. Additional support was provided by the Instituto de Salud Carlos III (ISCIII), grant numbers AC21_2/00024 (granted to J.C), and JPND-2023–1822-108 (granted to R.C.) as part of the JPND initiative JPND-2021–650-130. Additionally, CIC bioGUNE currently holds a Severo Ochoa Excellence accreditation, CEX2021-001136-S granted to J.C., also funded by Ministerio de Ciencia e Innovación/AEI /https://doi.org/10.13039/501100011033. E.F.-M. received funding from Fundación Tatiana Pérez de Guzmán el Bueno, grant BN661-FTPGB-2023. Transgenic Facility, directed by M.A.S.-M., is supported by Instituto de Salud Carlos III (ISCIII), co-funded by the European Union grant PT23/00123. This work also received funding from the Creutzfeldt-Jakob Disease Foundation—2022. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

The L108I polymorphism in mouse prion protein drives spontaneous disease and enhances transmission of atypical and classical prion strains

  • Eraña, Hasier
  • Vidal, Enric
  • Fernández-Borges, Natalia
  • Charco, Jorge M
  • Díaz-Domínguez, Carlos M
  • Sampedro-Torres-Quevedo, Cristina
  • Galarza-Ahumada, Josu
  • Fernández-Muñoz, Eva
  • San-Juan-Ansoleaga, Maitena
  • Pérez-Castro, Miguel Ángel
  • Gonçalves-Anjo, Nuno
  • Piñeiro, Patricia
  • Giler, Samanta
  • González-Martín, Nora
  • Lorenzo, Nuria L.
  • Manero-Azua, Africa
  • de Nanclares, Guiomar P.
  • Geijo, Mariví
  • Sánchez-Martín, Manuel A
  • Requena, Jesús R.
  • Castilla, Joaquín
Prion diseases are fatal neurodegenerative disorders that can be idiopathic, associated with genetic mutations, or acquired by infection with misfolded prion protein. We developed two complementary transgenic mouse models to investigate how the L108I substitution in mouse prion protein (PrP) influences spontaneous prion formation and transmission characteristics. The transgenic mouse model overexpressing the variant at approximately three times wild-type (WT) PrP levels (TgMo(L108I)3x) consistently developed a spontaneous neurodegenerative disorder between 219 and 536 days of age with 100% penetrance. This spontaneous disease exhibited biochemical and neuropathological characteristics of atypical prion disorders, featuring a distinctive 7–10 kDa protease-resistant PrP fragment and pathology comparable to small ruminants' atypical scrapie and certain forms of Gerstmann–Sträussler–Scheinker syndrome (GSS). In contrast, the knock-in model expressing the same variant at physiological levels (TgMo(L108I)1x) showed no spontaneous disease beyond 600 days, demonstrating that both the specific amino acid substitution and elevated expression levels are necessary for spontaneous prion formation. The spontaneously generated prions transmitted efficiently to models expressing the I108 variant and to Tga20 mice overexpressing WT PrP but encountered a robust transmission barrier toward WT mice, indicating strain-specific replication requirements. The TgMo(L108I)3x model demonstrated exceptional versatility as a universal acceptor for heterogeneous prion isolates, demonstrating superior efficiency in propagating atypical variants like GSS A117V (57 ± 0.6 days) and rapid propagation of classical scrapie-derived mouse prion strains, including Rocky Mountains Laboratory mouse prion strain (RML) (85 ± 3.8 days) and 22L (95 ± 1 days). Comparative analysis revealed that the L108I substitution differentially impacts strain propagation, with greater acceleration of RML (~33% shorter incubation) than 22L (~0.5% shorter) compared to WT mice. These complementary systems offer powerful experimental platforms for investigating the molecular determinants of spontaneous prion formation, strain selection and transmission barriers, providing insights into idiopathic prion pathogenesis and developing therapeutic interventions., The present work was partially funded by three different grants awarded by “Agencia Estatal de Investigación, Ministerio de Ciencia e Innovación” (Spanish Government), grant numbers PID2024-160022OB-I00, PID2021-122201OB-C21 granted to Joaquín Castilla, PID2020-117465GB-I00 granted to Jesús R. Requena, and PID2021-1222010B-C22 granted to Enric Vidal, funded by MCIN/AEI/10.13039/501100011033 and co-financed by the European Regional Development Fund (ERDF). EFA031/01 NEURO-COOP, which is co-funded at 65% by the European Union through Programa Interreg VI-A España-Francia-Andorra (POCTEFA 2021–2027) granted to Joaquín Castilla, Hasier Eraña and Enric Vidal. Additionally, CIC bioGUNE currently holds a Severo Ochoa Excellence accreditation, CEX2021-001136-S granted to Joaquín Castilla, also funded by Ministerio de Ciencia e Innovación/AEI/10.13039/501100011033. Transgenic Facility of IBSAL-University of Salamanca, directed by Manuel A. Sánchez‑Martín, is supported by Instituto de Salud Carlos III (ISCIII), co-funded by the European Union grant PT23/00123. Eva Fernández-Muñoz received funding from Fundación Tatiana Pérez de Guzmán el Bueno, grant BN661-FTPGB-2023. This work also received funding from the Creutzfeldt-Jakob Disease Foundation—2022. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Cofactors facilitate bona fide prion misfolding in vitro but are not necessary for the infectivity of recombinant murine prions

  • Pérez-Castro, Miguel Ángel
  • Eraña, Hasier
  • Vidal, Enric
  • Charco, Jorge M.
  • Lorenzo, Nuria L.
  • Gonçalves-Anjo, Nuno
  • Galarza-Ahumada, Josu
  • Díaz-Domínguez, Carlos M.
  • Piñeiro, Patricia
  • González-Miranda, Ezequiel
  • Giler, Samanta
  • Telling, Glenn
  • Sánchez-Martín, Manuel A.
  • Garrido, Joseba
  • Geijo, Mariví
  • Requena, Jesús R.
  • Castilla, Joaquín
Prion diseases, particularly sporadic cases, pose a challenge due to their complex nature and heterogeneity. The underlying mechanism of the spontaneous conversion from PrPC to PrPSc, the hallmark of prion diseases, remains elusive. To shed light on this process and the involvement of cofactors, we have developed an in vitro system that faithfully mimics spontaneous prion misfolding using minimal components. By employing this PMSA methodology and introducing an isoleucine residue at position 108 in mouse PrP, we successfully generated recombinant murine prion strains with distinct biochemical and biological properties. Our study aimed to explore the influence of a polyanionic cofactor in modulating strain selection and infectivity in de novo-generated synthetic prions. These results not only validate PMSA as a robust method for generating diverse bona fide recombinant prions but also emphasize the significance of cofactors in shaping specific prion conformers capable of crossing species barriers. Interestingly, once these conformers are established, our findings suggest that cofactors are not necessary for their infectivity. This research provides valuable insights into the propagation and maintenance of the pathobiological features of cross-species transmissible recombinant murine prion and highlights the intricate interplay between cofactors and prion strain characteristics., The present work was partially funded by three different grants awarded by “Agencia Estatal de Investigación, Ministerio de Ciencia e Innovación” (Spanish Government), grant numbers PID2021-122201OB-C21 granted to J.C., PID2021-1222010B-C22 granted to E.V., and PID2020-117465GB-I00 granted to J.R.R., funded by MCIN/ AEI /10.13039/501100011033 and co-financed by the European Regional Development Fund (ERDF). EFA031/01 NEURO-COOP, which is co-funded at 65% by the European Union through Programa Interreg VI-A España-Francia-Andorra (POCTEFA 2021-2027) granted to J.C. and H.E. Additional funding was provided by the Instituto de Salud Carlos III (ISCIII), grant number AC21_2/00024, granted to J.C. Additionally, CIC bioGUNE currently holds a Severo Ochoa Excellence accreditation, CEX2021-001136-S granted to J.C., also funded by Ministerio de Ciencia e Innovación/AEI /10.13039/501100011033. Transgenic Facility, directed by M.A.S.-M., is supported by Instituto de Salud Carlos III (ISCIII), co-funded by the European Union grant PT23/00123. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Conservation of strain properties of bank vole-adapted chronic wasting disease in the absence of glycosylation and membrane anchoring

  • Vidal, Enric
  • Eraña, Hasier
  • Charco, Jorge M.
  • Lorenzo, Nuria L.
  • Giler, Samanta
  • Ordóñez, Montserrat
  • Fernández-Muñoz, Eva
  • San-Juan-Ansoleaga, Maitena
  • Telling, Glenn C.
  • Sánchez-Martín, Manuel A.
  • Geijo, Mariví
  • Requena, Jesús R.
  • Castilla, Joaquín
Prion disease phenotypes (prion strains) are primarily determined by the specific misfolded conformation of the cellular prion protein (PrPC). However, post-translational modifications, including glycosyl phosphatidyl inositol (GPI) membrane anchoring and glycosylation, may influence strain characteristics. We investigated whether these modifications are essential for maintaining the unique properties of bank vole-adapted Chronic Wasting Disease (CWD-vole), the fastest known prion strain. Using a novel transgenic mouse model expressing I109 bank vole PrPC lacking the GPI anchor and largely devoid of glycans, we performed serial passages of CWD-vole prions. Despite elongated initial incubation periods, the strain maintained 100 % attack rate through three passages. Although the pathological phenotype showed characteristic GPI-less features, including abundant extracellular plaque formation, three subsequent serial passages in fully glycosylated and GPI-anchored bank vole I109 PrPC expressing transgenic mice TgVole (1×) demonstrated that the strain's distinctive rapid propagation properties were preserved. These findings suggest that neither GPI anchoring nor glycosylation are essential for maintaining CWD-vole strain properties, supporting the concept that strain characteristics are primarily encoded in the protein's misfolded structure., The present work was partially funded by three different grants awarded by “Agencia Estatal de Investigación, Ministerio de Ciencia e Innovación” (Spanish Government), grant numbers PID2021-122201OB-C21 and PID2021-1222010B-C22, and co-financed by the European Regional Development Fund (ERDF). EFA031/01 NEURO-COOP, which is co-funded at 65 % by the European Union through Programa Interreg VI-A España-Francia-Andorra (POCTEFA 2021–2027). Additional funding was provided by the Instituto de Salud Carlos III (ISCIII), grant number AC21_2/00024 as member of a JPND grant JPND-2021-650-130. Additionally, CICbioGUNE currently holds a Severo Ochoa Excellence accreditation, CEX2021-001136-S, also funded by MCIN/AEI/10.13039/501100011033. Transgenic Facility, directed by M.A. S-M, is supported by Instituto de Salud Carlos III (ISCIII), co-funded by the European Union grant PT23/00123. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript., info:eu-repo/semantics/publishedVersion
IRTA Pubpro. Open Digital Archive
Publicación Artículo científico (JournalArticle)

Overexpression of bank vole PrP(I109) in mice induces a spontaneous atypical prion disease with sex-dependent onset, early NfL elevation, and universal prion strain permissiveness

  • Eraña, Hasier
  • Vidal, Enric
  • Fernández-Borges, Natalia
  • Charco, Jorge M.
  • Díaz‑Domínguez, Carlos M.
  • Sampedro-Torres-Quevedo, Cristina
  • San-Juan-Ansoleaga, Maitena
  • Fernández-Muñoz, Eva
  • Galarza-Ahumada, Josu
  • Pérez-Castro, Miguel Ángel
  • Gonçalves-Anjo, Nuno
  • Piñeiro, Patricia
  • Pirisinu, Laura
  • Di Bari, Michele Angelo
  • Giler, Samanta
  • Raimondi, Ilaria
  • Espinosa, Juan Carlos
  • Vanni, Ilaria
  • D’Agostino, Claudia
  • Rodríguez-Cuesta, Juan
  • Pasetto, Laura
  • Bonetto, Valentina
  • González-Martín, Nora
  • Teijeira, Susana
  • Zou, Wen-Quan
  • Geijo, Mariví
  • Torres, Juan María
  • Chiesa, Roberto
  • Sánchez‑Martín, Manuel A.
  • Nonno, Romolo
  • Requena, Jesús R.
  • Castilla, Joaquín
Transgenic mice overexpressing bank vole prion protein with the isoleucine 109 polymorphism, TgVole(I109)4x, develop spontaneous neurodegenerative disease with sex-dependent onset, averaging 170 days in females and 200 days in males at terminal stage. The clinical and pathological features closely resemble Gerstmann-Sträussler-Scheinker syndrome (GSS), with characteristic ataxia, dysmetria, kyphosis, and prominent PrP plaques. Biochemical analysis reveals an atypical prion protein banding pattern with a distinctive low molecular weight band (7–10 kDa) following proteinase K digestion, similar to other atypical prion diseases such as small ruminants atypical scrapie (AS). Importantly, these spontaneously generated prions are highly infectious when passaged to mice expressing the same I109 polymorphism as well as to wild bank voles carrying the I109 polymorphism, but not to models expressing the methionine variant at this position, demonstrating the critical role of this specific polymorphism in atypical prion propagation. Temporal analysis reveals that infectious prions emerge significantly (2–3 months) before clinical signs appear, offering important insights into the pre-clinical phase of prion diseases. Serum neurofilament light chain levels increase significantly at 80 days of age, approximately 100 days before clinical onset, providing a wide therapeutic window with a reliable biomarker. The TgVole(I109)4× model exhibits extraordinary versatility in propagating diverse prion strains, showing remarkable susceptibility to atypical prions (including GSS and AS) with exceptionally short incubation periods, while maintaining the ability to efficiently propagate classical and recombinant prion strains. We present here a thoroughly characterized transgenic mouse model that spontaneously develops an atypical, bona fide prion disease with sex-related differences in disease onset. This model offers valuable insights into spontaneous and atypical prionopathies while demonstrating exceptional versatility for studying diverse prion strains and potential utility for evaluating therapeutic interventions when used with appropriate study designs that account for individual variability., The present work was partially funded by five different grants awarded by “Agencia Estatal de Investigación, Ministerio de Ciencia e Innovación” (Spanish Government), grant numbers PID2024-160022OB-I00, PID2021-122201OB-C21 granted to J.C., PID2021-1222010B-C22 granted to E.V., and PID2023-146146NB-I00 to J.C.E. funded by MCIN/AEI/https://doi.org/10.13039/501100011033 and co-financed by the European Regional Development Fund (ERDF), UE and PID2020-117465GB-I00 granted to J.R.R., funded by MICIU/AEI/https://doi.org/10.13039/501100011033. EFA031/01 NEURO-COOP, which is co-funded at 65% by the European Union through Programa Interreg VI-A España-Francia-Andorra (POCTEFA 2021–2027) granted to J.C. and H.E. Additional support was provided by the Instituto de Salud Carlos III (ISCIII), grant numbers AC21_2/00024 (granted to J.C), and JPND-2023–1822-108 (granted to R.C.) as part of the JPND initiative JPND-2021–650-130. Additionally, CIC bioGUNE currently holds a Severo Ochoa Excellence accreditation, CEX2021-001136-S granted to J.C., also funded by Ministerio de Ciencia e Innovación/AEI /https://doi.org/10.13039/501100011033. E.F.-M. received funding from Fundación Tatiana Pérez de Guzmán el Bueno, grant BN661-FTPGB-2023. Transgenic Facility, directed by M.A.S.-M., is supported by Instituto de Salud Carlos III (ISCIII), co-funded by the European Union grant PT23/00123. This work also received funding from the Creutzfeldt-Jakob Disease Foundation—2022. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript., info:eu-repo/semantics/publishedVersion
IRTA Pubpro. Open Digital Archive
Publicación Artículo científico (JournalArticle)

The L108I polymorphism in mouse prion protein drives spontaneous disease and enhances transmission of atypical and classical prion strains

  • Eraña, Hasier
  • Vidal, Enric
  • Fernández-Borges, Natalia
  • Charco, Jorge M
  • Díaz-Domínguez, Carlos M
  • Sampedro-Torres-Quevedo, Cristina
  • Galarza-Ahumada, Josu
  • Fernández-Muñoz, Eva
  • San-Juan-Ansoleaga, Maitena
  • Pérez-Castro, Miguel Ángel
  • Gonçalves-Anjo, Nuno
  • Piñeiro, Patricia
  • Giler, Samanta
  • González-Martín, Nora
  • Lorenzo, Nuria L.
  • Manero-Azua, Africa
  • de Nanclares, Guiomar P.
  • Geijo, Mariví
  • Sánchez-Martín, Manuel A
  • Requena, Jesús R.
  • Castilla, Joaquín
Prion diseases are fatal neurodegenerative disorders that can be idiopathic, associated with genetic mutations, or acquired by infection with misfolded prion protein. We developed two complementary transgenic mouse models to investigate how the L108I substitution in mouse prion protein (PrP) influences spontaneous prion formation and transmission characteristics. The transgenic mouse model overexpressing the variant at approximately three times wild-type (WT) PrP levels (TgMo(L108I)3x) consistently developed a spontaneous neurodegenerative disorder between 219 and 536 days of age with 100% penetrance. This spontaneous disease exhibited biochemical and neuropathological characteristics of atypical prion disorders, featuring a distinctive 7–10 kDa protease-resistant PrP fragment and pathology comparable to small ruminants' atypical scrapie and certain forms of Gerstmann–Sträussler–Scheinker syndrome (GSS). In contrast, the knock-in model expressing the same variant at physiological levels (TgMo(L108I)1x) showed no spontaneous disease beyond 600 days, demonstrating that both the specific amino acid substitution and elevated expression levels are necessary for spontaneous prion formation. The spontaneously generated prions transmitted efficiently to models expressing the I108 variant and to Tga20 mice overexpressing WT PrP but encountered a robust transmission barrier toward WT mice, indicating strain-specific replication requirements. The TgMo(L108I)3x model demonstrated exceptional versatility as a universal acceptor for heterogeneous prion isolates, demonstrating superior efficiency in propagating atypical variants like GSS A117V (57 ± 0.6 days) and rapid propagation of classical scrapie-derived mouse prion strains, including Rocky Mountains Laboratory mouse prion strain (RML) (85 ± 3.8 days) and 22L (95 ± 1 days). Comparative analysis revealed that the L108I substitution differentially impacts strain propagation, with greater acceleration of RML (~33% shorter incubation) than 22L (~0.5% shorter) compared to WT mice. These complementary systems offer powerful experimental platforms for investigating the molecular determinants of spontaneous prion formation, strain selection and transmission barriers, providing insights into idiopathic prion pathogenesis and developing therapeutic interventions., The present work was partially funded by three different grants awarded by “Agencia Estatal de Investigación, Ministerio de Ciencia e Innovación” (Spanish Government), grant numbers PID2024-160022OB-I00, PID2021-122201OB-C21 granted to Joaquín Castilla, PID2020-117465GB-I00 granted to Jesús R. Requena, and PID2021-1222010B-C22 granted to Enric Vidal, funded by MCIN/AEI/10.13039/501100011033 and co-financed by the European Regional Development Fund (ERDF). EFA031/01 NEURO-COOP, which is co-funded at 65% by the European Union through Programa Interreg VI-A España-Francia-Andorra (POCTEFA 2021–2027) granted to Joaquín Castilla, Hasier Eraña and Enric Vidal. Additionally, CIC bioGUNE currently holds a Severo Ochoa Excellence accreditation, CEX2021-001136-S granted to Joaquín Castilla, also funded by Ministerio de Ciencia e Innovación/AEI/10.13039/501100011033. Transgenic Facility of IBSAL-University of Salamanca, directed by Manuel A. Sánchez‑Martín, is supported by Instituto de Salud Carlos III (ISCIII), co-funded by the European Union grant PT23/00123. Eva Fernández-Muñoz received funding from Fundación Tatiana Pérez de Guzmán el Bueno, grant BN661-FTPGB-2023. This work also received funding from the Creutzfeldt-Jakob Disease Foundation—2022. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript., info:eu-repo/semantics/publishedVersion
IRTA Pubpro. Open Digital Archive
Publicación Artículo científico (JournalArticle)

Cofactors facilitate bona fide prion misfolding in vitro but are not necessary for the infectivity of recombinant murine prions

  • Pérez-Castro, Miguel Ángel
  • Eraña, Hasier
  • Vidal, Enric
  • Charco, Jorge M.
  • Lorenzo, Nuria L.
  • Gonçalves-Anjo, Nuno
  • Galarza-Ahumada, Josu
  • Díaz-Domínguez, Carlos M.
  • Piñeiro, Patricia
  • González-Miranda, Ezequiel
  • Giler, Samanta
  • Telling, Glenn
  • Sánchez-Martín, Manuel A.
  • Garrido, Joseba
  • Geijo, Mariví
  • Requena, Jesús R.
  • Castilla, Joaquín
Prion diseases, particularly sporadic cases, pose a challenge due to their complex nature and heterogeneity. The underlying mechanism of the spontaneous conversion from PrPC to PrPSc, the hallmark of prion diseases, remains elusive. To shed light on this process and the involvement of cofactors, we have developed an in vitro system that faithfully mimics spontaneous prion misfolding using minimal components. By employing this PMSA methodology and introducing an isoleucine residue at position 108 in mouse PrP, we successfully generated recombinant murine prion strains with distinct biochemical and biological properties. Our study aimed to explore the influence of a polyanionic cofactor in modulating strain selection and infectivity in de novo-generated synthetic prions. These results not only validate PMSA as a robust method for generating diverse bona fide recombinant prions but also emphasize the significance of cofactors in shaping specific prion conformers capable of crossing species barriers. Interestingly, once these conformers are established, our findings suggest that cofactors are not necessary for their infectivity. This research provides valuable insights into the propagation and maintenance of the pathobiological features of cross-species transmissible recombinant murine prion and highlights the intricate interplay between cofactors and prion strain characteristics., The present work was partially funded by three different grants awarded by “Agencia Estatal de Investigación, Ministerio de Ciencia e Innovación” (Spanish Government), grant numbers PID2021-122201OB-C21 granted to J.C., PID2021-1222010B-C22 granted to E.V., and PID2020-117465GB-I00 granted to J.R.R., funded by MCIN/ AEI /10.13039/501100011033 and co-financed by the European Regional Development Fund (ERDF). EFA031/01 NEURO-COOP, which is co-funded at 65% by the European Union through Programa Interreg VI-A España-Francia-Andorra (POCTEFA 2021-2027) granted to J.C. and H.E. Additional funding was provided by the Instituto de Salud Carlos III (ISCIII), grant number AC21_2/00024, granted to J.C. Additionally, CIC bioGUNE currently holds a Severo Ochoa Excellence accreditation, CEX2021-001136-S granted to J.C., also funded by Ministerio de Ciencia e Innovación/AEI /10.13039/501100011033. Transgenic Facility, directed by M.A.S.-M., is supported by Instituto de Salud Carlos III (ISCIII), co-funded by the European Union grant PT23/00123. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript., info:eu-repo/semantics/publishedVersion
IRTA Pubpro. Open Digital Archive
Publicación Artículo científico (JournalArticle)

Conservation of strain properties of bank vole-adapted chronic wasting disease in the absence of glycosylation and membrane anchoring

  • Vidal, Enric
  • Eraña, Hasier
  • Charco, Jorge M.
  • Lorenzo, Nuria L.
  • Giler, Samanta
  • Ordóñez, Montserrat
  • Fernández-Muñoz, Eva
  • San-Juan-Ansoleaga, Maitena
  • Telling, Glenn C.
  • Sánchez-Martín, Manuel A.
  • Geijo, Mariví
  • Requena, Jesús R.
  • Castilla, Joaquín
Prion disease phenotypes (prion strains) are primarily determined by the specific misfolded conformation of the cellular prion protein (PrPC). However, post-translational modifications, including glycosyl phosphatidyl inositol (GPI) membrane anchoring and glycosylation, may influence strain characteristics. We investigated whether these modifications are essential for maintaining the unique properties of bank vole-adapted Chronic Wasting Disease (CWD-vole), the fastest known prion strain. Using a novel transgenic mouse model expressing I109 bank vole PrPC lacking the GPI anchor and largely devoid of glycans, we performed serial passages of CWD-vole prions. Despite elongated initial incubation periods, the strain maintained 100 % attack rate through three passages. Although the pathological phenotype showed characteristic GPI-less features, including abundant extracellular plaque formation, three subsequent serial passages in fully glycosylated and GPI-anchored bank vole I109 PrPC expressing transgenic mice TgVole (1×) demonstrated that the strain's distinctive rapid propagation properties were preserved. These findings suggest that neither GPI anchoring nor glycosylation are essential for maintaining CWD-vole strain properties, supporting the concept that strain characteristics are primarily encoded in the protein's misfolded structure., The present work was partially funded by three different grants awarded by “Agencia Estatal de Investigación, Ministerio de Ciencia e Innovación” (Spanish Government), grant numbers PID2021-122201OB-C21 and PID2021-1222010B-C22, and co-financed by the European Regional Development Fund (ERDF). EFA031/01 NEURO-COOP, which is co-funded at 65 % by the European Union through Programa Interreg VI-A España-Francia-Andorra (POCTEFA 2021–2027). Additional funding was provided by the Instituto de Salud Carlos III (ISCIII), grant number AC21_2/00024 as member of a JPND grant JPND-2021-650-130. Additionally, CICbioGUNE currently holds a Severo Ochoa Excellence accreditation, CEX2021-001136-S, also funded by MCIN/AEI/10.13039/501100011033. Transgenic Facility, directed by M.A. S-M, is supported by Instituto de Salud Carlos III (ISCIII), co-funded by the European Union grant PT23/00123. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript., info:eu-repo/semantics/publishedVersion